The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial

Parastoo Mirzabeigi, Amir Hooshang Mohammadpour, Mojtaba Salarifar, Kheirollah Gholami, Mojtaba Mojtahedzadeh, Mohammad Reza Javadi, Parastoo Mirzabeigi, Amir Hooshang Mohammadpour, Mojtaba Salarifar, Kheirollah Gholami, Mojtaba Mojtahedzadeh, Mohammad Reza Javadi

Abstract

Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovascular risk factors in patients with coronary artery disease (CAD). A total of 33 patients with CAD who fulfilled inclusion and exclusion criteria were entered the study. Patients were randomly assigned to receive curcumin or placebo, 500 mg capsules, four times daily for 8 weeks. Lipid profile, blood glucose and high sensitive C-reactive protein (hs-CRP) levels were analyzed at baseline and two months after treatment. Serum levels of triglycerides (P=0.01), LDL-cholesterol (P=0.03) and VLDL-cholesterol (P=0.04) significantly decreased in the curcumin group compared to baseline, without significant changes in total cholesterol, HDL-cholesterol, blood glucose and hs-CRP levels. In all mentioned laboratory parameters, significant difference was not detected between curcumin and placebo. Although curcumin improved some of lipid profile components, it did not show appreciable effect on inflammatory markers in patients with CAD. Therefore, more detailed assessment of metabolic effects or anti-inflammatory activities of curcumin need to perform by extensive human study.

Keywords: Blood glucose; Coronary artery disease; Curcumin; Lipid profile; hs-CRP.

References

    1. Wang TJ. New cardiovascular risk factors exist, but are they clinically useful? Eur. Heart J. 2008;29:441–444.
    1. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis. 2003;167:73–79.
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.
    1. Nasiripour S, Gholami Kh, Mousavi S, Mohagheghi A, Radfar M, Abdollahi M, Khazaeipour Z, Mojtahedzadeh M. Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with st-segment elevated myocardial infarction: a prospective open label pilot clinical trial. Iran. J. Pharm. Res. 2014;13:583–590.
    1. Acharjee S, Qin J, Murphy SA, McCabe C, Cannon CP. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 Trial) Am. J. Cardiol. 2010;105:619–623.
    1. Kohli K, Ali J, Ansari MJ, Raheman Z. Curcumin: a natural antiinflammatory agent. Indian J. Pharmacol. 2005;3:141–147.
    1. Kapakos G, Youreva V, Srivastava A. Cardiovascular protection by curcumin: molecular aspects. Indian J. Biochem. Biophys. 2012;49:306–315.
    1. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as curecumin: from kitchen to clinic. Biochem. Pharmacol. 2008;75:787–809.
    1. Hamed OA, Mehdawi N, Taha AA, Hamed EM, Al-Nuri MA, Hussein AS. Synthesis and antibacterial activity of novel curcumin derivatives containing heterocyclic moiety. Iran. J. Pharm. Res. 2013;12:47–56.
    1. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, James Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC. Compl. Altern. Med. 2006;6:10–13.
    1. Quiles JL, Aguilera C, Mesa MD, Ramirez-Tortosa MC, Baro L, Gil A. An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors. 1998;8:51–57.
    1. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int. J .Cardiol. 2009;133:145–151.
    1. Ramirez-TortosaMC , Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis. 1999;147:371–378.
    1. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J. Physiol. Pharmacol. 2005;56:627–635.
    1. Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr. Res. Pract. 2010;4:191–195.
    1. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 1992;36:273–275.
    1. Ramirez-Bosca A, Soler A, Carrion MA, Mira DP, Zapata JP, Diaz J, Bernd A, Almagro EQ, Miquel J. Anhydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech. Ageing. Dev. 2000;119:41–47.
    1. Baum L, Cheunga SK, Mok V, Lamb CW, Leung V, Hui E, Ng C, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng KF, Fong C, Lee JS, Chanh MH, Szeto S, Lui V, Tsoh J, Kwok T, Chang IH, Lam CW. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 2007;56:509–514.
    1. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta. Med. Indones. 2008;40:201–210.
    1. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in-vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother. Res. 2011;25:1721–1726.
    1. Feng D, Ohlsson L, Duan R. Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression. Lipids Health Dis. 2010;9:40.
    1. Mahesh T, Sri Balasubashini MM, Menon VP. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats: effect on lipid peroxidation. Therapie. 2004;59:639–644.
    1. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol. Pharm. Bull. 2005;28:937–939.
    1. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J. Agric. Food Chem. 2005;53:959–963.
    1. Best L, Elliott AC, Brown PD. Curcumin induces electrical activity in rat pancreatic b-cells by activating the volume- regulated anion channel. Biochem. Pharmacol. 2007;73:1768–1775.
    1. Seo K, Choi M, Jung U, Kim H, Yeo J, Jeon S, Lee M. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol. Nutr. Food Res. 2008;52:1–10.
    1. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J. Surg. Res. 2005;125:109–116.
    1. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y, Nagai R. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis. 2006;185:39–46.
    1. Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: A novel anti-inflammatory role for curcumin. Mol. Nutr. Food Res. 2008;52:987–994.
    1. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 2005;50:2191–193.
    1. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane) Indian J. Med. Res. 1980;71:632–634.
    1. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2006;4:1502–1506.
    1. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J. Altern. Compl. Med. 2004;10:1015–1008.
    1. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986;24:651–654.
    1. Lal B, Kapoor AK, Aggrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother. Res. 2000;14:443–447.
    1. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 2007;595:453–470.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere